TrialLeukemia2001

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study.

S Trudel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.